DAVID HAUSER: Open Payments
NPI 1992006852 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,621 in 91 payments from 16 companies in 2025. Trend: 2023 $225 · 2024 $1,026 · 2025 $1,621
Food & beverage: $1,622
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $334 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $238 |
| Vanda Pharmaceuticals Inc. | 11 | $226 |
| Corium, LLC | 10 | $222 |
| Lundbeck LLC | 9 | $165 |
| Axsome Therapeutics, Inc. | 4 | $89 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Biogen, Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Neurocrine BioSciences, Inc. | 2 | $41 |
Products named: VRAYLAR, CAPLYTA, REXULTI, FANAPT, Azstarys, Auvelity, ZURZUVAE, TRINTELLIX.
Industry payments across AZ — which companies pay providers there.
